New Echocardiographic Parameters for Prediction of Response to Cardiac Resynchronization Therapy (NEW-CRT)
New Approaches to Echocardiography Assessment of Cardiac Dyssynchrony: Relevance Concerning Response Rate to Cardiac Resynchronization Therapy
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
BW
-
Heidelberg, BW, Germany, 69120
- Department of Cardiology, University of Heidelberg
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- congestive heart failure, dilated cardiomyopathy, indication for implantation of a CRT-device according to the European Society of Cardiology (ESC)
Exclusion Criteria:
- persons who are incapable of giving informed consent
- acute heart attack
- arrhythmia during the examination (such as atrial fibrillation and frequent VES)
- state after STEMI with an extended scar
- inotropic drug therapy
- pre-existing permanent pacemaker stimulation
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
3D echocardiography
Time Frame: 12 months
|
offline analysis of echocardiography data
|
12 months
|
|
2D strain
Time Frame: 12 months
|
offline analysis of echocardiography data
|
12 months
|
|
m-mode echocardiography
Time Frame: 12 months
|
offline analysis of echocardiography data
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
NYHA
Time Frame: 12 months
|
New York Heart Association (NYHA) functional classification
|
12 months
|
|
six-min walk test
Time Frame: 12 months
|
distance walked over 6 minutes as a sub-maximal test of aerobic capacity
|
12 months
|
|
NT-proBNP
Time Frame: 12 months
|
N-terminal prohormone of brain natriuretic peptide (NT-proBNP)
|
12 months
|
|
LV EF
Time Frame: 12 month
|
left ventricular (LV) ejection fraction (EF)
|
12 month
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Mathias Konstandin, M.D., Heidelberg University
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- S-553/2012
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.